Condition: Neovascular Age-related Macular Degeneration · Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
This description comes directly from the study's public registry record.
Yating Liu · 86 15821084695 · yating.liu@innoventbio.com
Always discuss trial participation with your own doctor first.
| Shanghai general hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07275840